インスリン グラルギン
参考資料

↑  “Insulin glargine Use During Pregnancy”. Drugs.com (6 April 2020). 4 September 2020閲覧。
↑  “Lantus 100 units/ml solution for injection in a cartridge - Summary of Product Characteristics (SmPC)”. (emc). 7 May 2020閲覧。
↑  “Lantus- insulin glargine injection, solution Lantus SoloStar- insulin glargine injection, solution”. DailyMed. 29 July 2021閲覧。
↑  “Lantus EPAR”. European Medicines Agency (EMA). 28 July 2021閲覧。
↑  “Toujeo EPAR”. European Medicines Agency (EMA). 28 July 2021閲覧。
1 2 3 4 5 6 7 8 9 10 11  “Insulin Glargine Monograph for Professionals”. Drugs.com.   AHFS. 23 December 2018閲覧。
↑   British national formulary: BNF 76 (76th ed.). Pharmaceutical Press. (2018). p. 701. ISBN 9780857113382
↑  “Insulin Glargine Monograph for Professionals”. Drugs.com.   AHFS. 23 December 2018閲覧。
1 2  “ランタスXR注ソロスター CTD 第二部”.   PMDA. 2022年1月19日閲覧。
↑   World Health Organization model list of essential medicines: 22nd list (2021). Geneva: World Health Organization. (2021). hdl:10665/345533. WHO/MHP/HPS/EML/2021.02
1 2 3 4  “ランタス注100単位／mL 添付文書”. www.info.pmda.go.jp. 2022年1月19日閲覧。
1 2 3 4  “ランタスXR注ソロスター 添付文書”. www.info.pmda.go.jp. 2022年1月19日閲覧。
↑  Waugh, N; Cummins, E; Royle, P; Clar, C; Marien, M; Richter, B; Philip, S (July 2010). “Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation”. Health Technology Assessment 14 (36):  1–248. doi:10.3310/hta14360. PMID 20646668. http://wrap.warwick.ac.uk/44115/2/WRAP_Waugh_Newer_agents_blood.pdf.
↑  “Efficacy and safety of insulin analogues for the management of diabetes mellitus: a meta-analysis”. CMAJ 180 (4):  385–97. (February 2009). doi:10.1503/cmaj.081041. PMC 2638025. PMID 19221352. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2638025/.
↑  “Cost-Effectiveness of Insulin Degludec Versus Insulin Glargine U300 in the Netherlands: Evidence From a Randomised Controlled Trial”. Advances in Therapy 37 (5):  2413-2426. (April 2020). doi:10.1007/s12325-020-01332-y. PMC 7467476. PMID 32306247. https://link.springer.com/article/10.1007/s12325-020-01332-y.
↑  American Diabetes Association (2003). “Position statement: Insulin administration”. Diabetes Care 26 (Suppl. 1):  121–124. doi:10.2337/diacare.26.2007.S121. PMID 12502637.
↑  Kaplan, W. (2004). “Effects of Mixing Glargine and Short-Acting Insulin Analogs on Glucose Control”. Diabetes Care 27 (11):  2739–2740. doi:10.2337/diacare.27.11.2739. PMID 15505016.
↑  Rendell, M; Akturk, HK; Tella, SH (March 2013). “Glargine safety, diabetes and cancer.”. Expert Opinion on Drug Safety 12 (2):  247–63. doi:10.1517/14740338.2013.770469. PMID 23394441.
↑  Tang, X; Yang, L; He, Z; Liu, J (2012). “Insulin glargine and cancer risk in patients with diabetes: a meta-analysis.”. PLOS ONE 7 (12):  e51814. Bibcode: 2012PLoSO...751814T. doi:10.1371/journal.pone.0051814. PMC 3526637. PMID 23284776. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3526637/.
↑  Bolli, G. (1999). “Insulin analogues and their potential in the management of diabetes mellitus.”. Diabetologia 42 (10):  1151–1167. doi:10.1007/s001250051286. PMID 10525654.
↑  “Lantus EPAR”. European Medicines Agency (EMA). 7 May 2020閲覧。
↑  EPAR Lantus Archived 22 November 2006 at the Wayback Machine., German summary of admission report of EMEA (PDF)
↑  "Sanofi Receives FDA Approval of Once-Daily Basal Insulin Toujeo" (Press release). Sanofi. 25 February 2015. 2015年2月27日時点のオリジナルよりアーカイブ。
↑  “Toujeo: FDA-Approved Drugs”. U.S. Food and Drug Administration (FDA). 7 May 2020閲覧。
↑  “次世代の基礎インスリン「ランタスXR注ソロスター」承認取得 低血糖発現と体重増加が低下｜ニュース｜糖尿病ネットワーク”. ニュース｜糖尿病ネットワーク. 2022年1月19日閲覧。